Mainz Biomed BV
$ 1.17
0.86%
04 Dec - close price
- Market Cap 7,902,800 USD
- Current Price $ 1.17
- High / Low $ 1.20 / 1.11
- Stock P/E N/A
- Book Value 0.62
- EPS -5.28
- Next Earning Report 2026-04-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.14 %
- ROE -4.66 %
- 52 Week High 8.20
- 52 Week Low 0.92
About
None
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-28 | 2025-09-03 | 2025-05-30 | 2025-03-31 | 2024-10-21 | 2024-06-30 | 2024-04-09 | 2024-03-06 | 2023-11-16 | 2023-08-15 | 2023-04-27 | 2023-03-08 |
| Reported EPS | 0 | -2.65 | -7.71 | -7.71 | -19.6 | None | -0.24 | -0.24 | -0.39 | -0.56 | -0.45 | -0.46 |
| Estimated EPS | -2 | -2.4 | -2.8 | -6.4 | -0.15 | -9 | -0.32 | -0.3167 | -0.47 | -0.42 | -0.46 | -0.46 |
| Surprise | 2 | -0.25 | -4.91 | -1.31 | -19.45 | 0 | 0.08 | 0.0767 | 0.08 | -0.14 | 0.01 | 0 |
| Surprise Percentage | 100% | -10.4167% | -175.3571% | -20.4688% | -12966.6667% | None% | 25% | 24.2185% | 17.0213% | -33.3333% | 2.1739% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYNZ
2025-10-17 20:06:08
Weiss Ratings has reiterated its "Sell (E)" rating for Mainz Biomed (MYNZ). The report also highlights that Armistice Capital LLC recently increased its holdings in Mainz Biomed NV stock. Mainz Biomed develops and sells in-vitro diagnostic tests for early cancer detection, including ColoAlert for colorectal cancer and PancAlert for pancreatic cancer.
2025-10-15 15:12:17
Mainz Biomed N.V. announced its participation in the 2025 Maxim Growth Summit, scheduled for October 22-23, 2025, in New York City. The company will engage in one-on-one meetings with institutional investors and senior Maxim analysts, highlighting its molecular genetics diagnostic solutions, particularly ColoAlert® for colorectal cancer detection. The summit will feature industry leaders, keynote speakers like Larry Kudlow and Christopher Ruddy, and roundtable discussions across various sectors including biotechnology.
2025-10-15 13:03:51
Mainz Biomed N.V. announced its participation in the 2025 Maxim Growth Summit, where it will meet with institutional investors and senior Maxim analysts. The summit, held on October 22-23, 2025, brings together industry leaders and innovators to discuss trends across various sectors including biotechnology. Mainz Biomed specializes in early cancer detection with its flagship product ColoAlert® and other pipeline candidates like PancAlert.
2025-10-15 13:01:00
Mainz Biomed (NASDAQ:MYNZ) announced its participation in the 2025 Maxim Growth Summit in New York City on October 22-23, 2025. The company, which specializes in molecular genetics diagnostics for early cancer detection, will engage in one-on-one meetings with institutional investors and senior Maxim analysts. The summit will feature keynote speakers and roundtable sessions across various sectors including biotechnology and AI.
2024-12-19 13:01:00
Mainz Biomed has partnered with Quest Diagnostics for clinical trials and potential commercialization of its ColoAlert colorectal cancer screening test. Quest will provide lab services for the ReconAAsense FDA study, which involves 15,000 subjects across 150 US sites. This collaboration aims to advance the commercial development of ColoAlert, a stool-based DNA test, and address the significant market opportunity in colorectal cancer screening.
2024-11-29 08:45:00
Mainz Biomed has announced a 1-for-40 reverse stock split to increase its share price and comply with Nasdaq's minimum bid price requirement. The split is expected to become effective on December 3, 2024, and will reduce the number of ordinary shares outstanding while maintaining stockholders' percentage ownership. The company is actively working to address Nasdaq's continued listing standards, including the minimum bid price and stockholders' equity requirements.
